ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1684

Prolonged Remission/Low Disease Activity State Is Associated with a Better Health-Related Quality

Manuel Ugarte-Gil1,2, Rocío Gamboa-Cárdenas3, Mariela Medina-Chinchon3, Cristina Reategui-Sokolova3, Francisco Zevallos3, Claudia Elera-Fitzcarrald3,4, Victor R. Pimentel-Quiroz3, Erika Noriega1, Zoila Rodriguez-Bellido3,5, Cesar A. Pastor-Asurza3,5, Graciela S. Alarcón6,7 and Risto Perich-Campos3,5, 1Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, 2Rheumatology, Universidad Científica del Sur, Lima, Peru, 3Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, 4Universidad Científica del Sur, Lima, Peru, 5Universidad Nacional Mayor de San Marcos, Lima, Peru, 6Universidad Peruana Cayetano Heredia, Lima, Peru, 7Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: outcomes, remission and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Systemic Lupus Erythematosus – Clinical Poster II: Biomarkers and Outcomes

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Achieving remission and low lupus disease activity state (LDAS) in systemic lupus erythematosus (SLE) patients improves their prognosis in terms of damage accrual. But, the impact of these states on health-related quality of life (HRQoL) has only been sparsely assessed (1, 2). The aim of these analyses is to evaluate the association between the duration of remission and LDAS and HRQoL, after adjustment for possible confounders.

 

Methods: Patients from a single center cohort started in 2012 and who had at least two visits were included in this study. Visits were performed every six months. Socioeconomic and clinical data were recorded at every visit. Disease activity was ascertained with the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), disease damage with the SLICC/ACR Damage Index (SDI) and HRQoL with the Spanish version of the LupusQoL. Remission was defined as a SLEDAI-2K=0, prednisone<=5mg/d, immunosuppressants on maintenance dose, LDAS was defined as not on remission and a SLEDAI-2K<=4, prednisone<=7.5mg/d, immunosuppressants on maintenance dose. Disease activity states were recorded in each visit. The outcomes were each of the LupusQoL’s domains at the last visit. Univariable and multivariable lineal regression models, adjusted by age at diagnosis, disease duration, socioeconomic status, antimalarial use, damage, comorbidities and baseline value of the same domain were performed. Duration of remission/LDAS was categorized as <=25%; >25 but <=50%; >50 but <=75%; and >75. Due to the relatively small number of patients on remission, remission and LDAS were examined together.

 

Results: Two hundred and thirty-five patients were included, 217 (92.3%) were female, mean (SD) age at diagnosis was 35.42 (13.30) years. Disease duration at baseline was 7.32 (6.69) years. The mean follow-up was 3.29 (1.27) years, and they had 4.93 (1.99) visits. Mean percentages of visits on each state during the follow up were 24.23 (31.38) for remission 32.16 (32.63) for LDAS and 43.60 (38.71) for active. The association between the percentage of follow-up on remission/LDAS is depicted in Table 1.

 

Conclusion: A longer duration on remission/LDAS is associated with a better HRQoL (Physical Health, Pain, Fatigue and Burden to Others) independently of possible confounders.

 

1. Mok CC, Ho LY, Tse SM, Chan KL. Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus. Ann Rheum Dis. 2017;76(8):1420-5.

2. Golder V, Kandane-Rathnayake R, Hoi AY, Huq M, Louthrenoo W, An Y, et al. Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study. Arthritis Res Ther. 2017;19(1):62.

 


Disclosure: M. Ugarte-Gil, None; R. Gamboa-Cárdenas, None; M. Medina-Chinchon, None; C. Reategui-Sokolova, None; F. Zevallos, None; C. Elera-Fitzcarrald, None; V. R. Pimentel-Quiroz, None; E. Noriega, None; Z. Rodriguez-Bellido, None; C. A. Pastor-Asurza, None; G. S. Alarcón, None; R. Perich-Campos, None.

To cite this abstract in AMA style:

Ugarte-Gil M, Gamboa-Cárdenas R, Medina-Chinchon M, Reategui-Sokolova C, Zevallos F, Elera-Fitzcarrald C, Pimentel-Quiroz VR, Noriega E, Rodriguez-Bellido Z, Pastor-Asurza CA, Alarcón GS, Perich-Campos R. Prolonged Remission/Low Disease Activity State Is Associated with a Better Health-Related Quality [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/prolonged-remission-low-disease-activity-state-is-associated-with-a-better-health-related-quality/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prolonged-remission-low-disease-activity-state-is-associated-with-a-better-health-related-quality/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology